All data and related metadata were deposited in an appropriate public repository. The data on the study population that were obtained from the NHIRD (<http://w3.nhri.org.tw/nhird/date_01.html>) are maintained in the NHIRD (<http://nhird.nhri.org.tw/>). The NHRI is a nonprofit foundation established by the government.

Introduction {#sec005}
============

Osteoporosis is the most common type of bone disease \[[@pone.0168673.ref001]\] and is a major public health problem \[[@pone.0168673.ref002]\]. Osteoporosis increases the risk of breaking a bone \[[@pone.0168673.ref003]\]. Approximately 50% of women older than 50 years were predicted to fracture their hip, wrist, or vertebra (bone of the spine) during their lifetime. Studies have reported that one out of 4 osteoporotic hip fractures resulted in long-term nursing home care, and half of these patients are unable to walk without assistance and have a 24% increased risk of death within one year \[[@pone.0168673.ref004],[@pone.0168673.ref005]\].

Parathyroid hormone (PTH) stimulates osteoblasts, which increase the production of receptor activator of nuclear factor kappa-B ligand (RANKL) \[[@pone.0168673.ref006]\]. Hematopoietic cell precursors stimulated by macrophage colony-stimulating factor (M-CSF) facilitate osteoclast production that expresses RANK \[[@pone.0168673.ref006]\]. Osteoblasts also produce a decoy receptor called osteoprotegerin (OPG) that binds to RANKL and prevents RANKL and RANK interaction \[[@pone.0168673.ref007]\]. Estradiol increases the production of OPG to diminish bone resorption. Glucocorticoids stimulate RANKL expression and inhibit OPG synthesis by osteoblasts to enhance osteoclast proliferation and differentiation, leading to bone resorption \[[@pone.0168673.ref008]\].

Patient profiles at a bone health and osteoporosis prevention service center in Ireland revealed that only 13% of patients did not present with comorbidities \[[@pone.0168673.ref009]\]. Osteoporosis has been reported to be associated with hyperlipidemia, hypertension, diabetes, ischemic heart disease, end-stage renal disease \[[@pone.0168673.ref010]\], and liver cirrhosis \[[@pone.0168673.ref011]\]. Infections such as hepatitis C virus (HCV) infection are also risk factors of osteoporosis \[[@pone.0168673.ref011]\]. Osteoporotic changes \[[@pone.0168673.ref012]\] in tuberculosis arthritis were observed in previous report \[[@pone.0168673.ref013]\]. However, the respiratory tuberculosis (RT) intervention associated with bone fracture among patients with or without comorbidities is not found in literature.

Methods and Materials {#sec006}
=====================

Study population {#sec007}
----------------

The patient selection process used in our study is illustrated in [Fig 1](#pone.0168673.g001){ref-type="fig"}. We conducted a retrospective population-based cohort study to investigate the association between RT and risk of incident bone fracture and osteoporosis / fragility fracture. The diagnosis and treatment of the RT is under the strict control of the Centers for Disease Control in Taiwan for avoiding pulmonary tuberculosis (PTB) transmission \[[@pone.0168673.ref014]\]. The coding of the RT is after the consensus of the chest physician, infection specialist and the well-trained coder. The RT cohort follow up by the public nurse and chest physician or infection specialist. During the study period (1999--2005), we identified newly diagnosed patients with RT (ICD-9-CM 011--012) as the RT cohort, and the initial date of RT diagnosis served as their index date. We randomly selected comparison participants (individuals without RT) from the LHID as the non-RT cohort and frequency-matched the participants by age and sex at a ratio of 1:2. The index date of the non-RT cohort was randomly assigned a month and day with the same year as the matched cases. We excluded individuals with missing data such as date of birth, sex, and known history of osteoporosis / fragility fracture before the baseline from the study.

![Flow chart of the selection of study participants.](pone.0168673.g001){#pone.0168673.g001}

Outcome and comorbidities measurement {#sec008}
-------------------------------------

The primary endpoint of our study was the occurrence of fragility fracture (ICD-9-CM 733.1). The secondary endpoint was osteoporosis /fragility fracture (pathology fractures; ICD-9-CM 733.0, 733.1) \[[@pone.0168673.ref015]--[@pone.0168673.ref017]\]. All participants were followed up from the index date to the date when the participants stopped claiming insurance and showing signs of incident fragility fracture, osteoporosis / fragility fracture or until December 31, 2011.

Comorbidities were defined as the patient having used medical services for hyperlipidemia (ICD-9-CM 272), hypertension (ICD-9-CM 401--405), diabetes (ICD-9-CM 250), pneumonia (ICD-9-CM 480--488), liver cirrhosis (ICD-9-CM 571), ischemia heart disease (IHD, ICD-9-CM 410--414), end-stage renal disease (ESRD, ICD-9-CM 585), hyperparathyroidism (ICD-9-CM 252.0), celiac disease (ICD-9-CM 579.0), Crohn's disease (ICD-9-CM 555.0, 555.1, 555.2, and 555.9), alcohol-related illness (ICD-9-CM 291, 303, 305, 571.0, 571.1, 571.2, 571.3, and 790.3), stroke (ICD-9-CM 430--438), chronic obstructive pulmonary disease (COPD; ICD-9-CM 490--496), and lower body weight (ICD-9-CM 783.2) before the end date \[[@pone.0168673.ref018]\]. We also investigated drug effects and collected the history of oral steroid, bisphosphonates, hormone replacement therapy (HRT), vitamin D supplements, and aromatase inhibitors prescription before the end date. The oral steroid users was defined subjects had ever used the oral steroid at least one month \[[@pone.0168673.ref019]\]. Besides, the bisphosphonates, HRT, vitamin D supplements, and aromatase inhibitors were considered for adjustment, when subjects ever used for one dose before the study end date.

Ethics statement {#sec009}
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115). The IRB also specifically waived the consent requirement.

Statistical analysis {#sec010}
--------------------

We presented the mean and standard deviation (SD) for age and percentages for sex, age groups, occupation, comorbidities, and each type of drug used. We used the chi-squared test and Student's t-test to assess the differences in the distribution between the RT and non-RT cohorts. The incidence--density of fragility fracture, osteoporosis / incident fragility fracture were calculated as the number of patients with incident fragility fracture, osteoporosis / fragility fracture divided by the sum of person--years (per 1000 person--years). We also measured the cumulative incidence curves of incident fragility fracture, osteoporosis / fragility fracture for both cohorts by using the Kaplan--Meier method. We used the log-rank test to assess the different incidence curves. We demonstrated the incidence--density between the RT and non-RT cohorts after stratifying the data on the basis of sex, age, occupation, comorbidities, oral steroid used, follow-up period (\<2 and ≥2 years), and oral steroid use. The incidence rate ratio (IRR) of incident fragility fracture, osteoporosis / fragility fractures for these variables between the two cohorts was assessed using the Poisson regression model. The multivariable Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% and 98% confidence intervals (CIs) for the risk of incident fragility fracture, osteoporosis /fragility fracture between the two cohorts. The Bonferroni adjustment was used in multiple comparisons.

All the statistical analyses were performed using the SAS 9.4 statistical package (SAS Institute Inc., NC, USA). We used the R software (R Foundation for Statistical Computing, Vienna, Austria) to plot the cumulative incidence of both cohorts. A *p-value \< 0*.*05* and (*p-value \< 0*.*02*) was considered significant in the 2-tailed tests performed this study.

Results {#sec011}
=======

This study included 6612 patients with RT and 13220 normal controls from 1999 to 2005 ([Table 1](#pone.0168673.t001){ref-type="table"}). The frequency-matched cohorts demonstrated a similar age and sex distribution (*p-value* \> 0.05), in which 69.7% were men and 43.5% were ≧65 years old. Except for hypertension, celiac disease and Chron's disease, the percentage of comorbidities in the RT cohort was greater than that in the non-RT cohort. RT cohort used the oral steroid (51.5%) or bisphosphonates (1.53%) was more common than comparison cohort.

10.1371/journal.pone.0168673.t001

###### Comparison of demographics and comorbidity between with and without respiratory tuberculosis cohorts.

![](pone.0168673.t001){#pone.0168673.t001g}

                            Respiratory tuberculosis                        
  ------------------------- -------------------------- ------ ------ ------ ---------
  **Sex**                                                                   0.99
  Women                     4008                       30.3   2004   30.3   
  Men                       9212                       69.7   4608   69.7   
  **Age, year**                                                             0.99
  \<35                      2274                       17.2   1137   17.2   
  35--65                    5196                       39.3   2598   39.3   
  ≥65                       5750                       43.5   2877   43.5   
  Mean (SD)^\#^             56.7                       20.2   56.9   20.3   0.64
  **Occupation**                                                            \<0.001
  White collar              5685                       43.0   2468   37.3   
  Blue collar               4839                       36.6   2641   39.9   
  Others                    2696                       20.4   1503   22.7   
  **Comorbidity**                                                           
  Hyperlipidemia            3439                       26.0   1576   23.8   \<0.001
  Hypertension              6446                       48.8   3283   49.7   0.24
  Diabetes                  2909                       22.0   1793   27.1   \<0.001
  Pneumonia                 4712                       35.6   4019   60.8   \<0.001
  Live cirrhosis            3565                       27.0   2376   35.9   \<0.001
  IHD                       3597                       27.2   2038   30.8   \<0.001
  Stroke                    3319                       25.1   1806   27.3   \<0.001
  COPD                      5793                       43.8   4982   75.4   \<0.001
  ESRD                      183                        1.38   170    2.57   \<0.001
  Alcohol-related illness   374                        2.83   447    6.76   \<0.001
  Hyperparathyroidism       12                         0.09   18     0.27   0.002
  Celiac disease            0                          0.00   1      0.02   \-
  Chron's disease           236                        1.79   133    2.01   0.27
  Lower body weight         323                        2.44   286    4.33   \<0.001
  **Treatment**                                                             
  Oral steroid              4340                       32.8   3402   51.5   \<0.001
  Bisphosphonates           76                         0.57   101    1.53   \<0.001
  HRT                       1218                       9.21   651    9.85   0.15
  Vitamin D supplements     21                         0.16   12     0.18   0.71
  Aromatase inhibitors      13                         0.10   10     0.15   0.30

Chi-square test; ^\#^ Student's t-test; White collar: civil services, institution workers, enterprise, business and industrial administration personnel; Blue collar: farmers, fishermen, vendors, and industrial laborers; Others: retired, unemployed, and low-income populations; HRT, Hormone Replacement Therapy; IHD, ischemia heart disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease

The cumulative incidence of incident fragility fracture ([Fig 2A](#pone.0168673.g002){ref-type="fig"}, log-rank *P \< 0*.*001)* were significantly higher for patients in the RT cohort than for participants without RT. During the 44517 and 107232 person-years follow-up, the overall incidence density of fragility fractures was 1.69-fold significantly higher in RT patients than in the non-RT cohort (2.02 vs 1.11 per 1000 person-y), with an adjusted HR = 1.69 (95% CI = 1.26--2.28; 98% CI = 1.18--2.44) ([Table 2](#pone.0168673.t002){ref-type="table"}). Stratified by sex, men with RT had a 57% increased fragility fracture risk compared to the non-RT cohort. The RT cohort was significantly associated with a higher risk of fragility fracture compared with the non-RT cohort for aged of 65--75 years (adjusted HR = 1.76, 95% CI = 1.12--2.75; 98% CI = 1.02--3.03) and ≧75 years (adjusted HR = 1.94, 95% CI = 1.18--3.19; 98% CI = 1.06--3.56). The adjusted HR of fragility fracture was higher in RT cohort regardless of white collar (adjusted HR = 2.19, 95% CI = 1.21--3.97; 98% CI = 1.06--4.52). The risk of fragility fracture was observed in patients with comorbidities (adjusted HR = 1.90, 95% CI = 1.43--2.52; 98% CI = 1.34--2.68) in the RT cohort than in the non-RT cohort. Stratified by oral steroid, RT patients with oral steroid or without oral steroid had an increased fragility fracture risk compared to the non-RT cohort. The adjusted HR of fragility fracture was significantly higher in the more than two follow-up year (adjusted HR = 1.67, 95% CI = 1.16--2.40; 98% CI = 1.07--2.59).

![The cumulative incidence of incident bone fracture (A) and osteoporosis / fragility fracture (B) between non-respiratory tuberculosis cohort (solid line) and respiratory tuberculosis cohort (dashed line).](pone.0168673.g002){#pone.0168673.g002}

10.1371/journal.pone.0168673.t002

###### Incidence and adjusted hazard ratio of Incident fragility fractures stratified by sex, age, comorbidity, oral steroid used and follow-up time between with and without respiratory tuberculosis cohorts.
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                        Respiratory tuberculosis                                                                                                                                                               
  --------------------- -------------------------- -------- ------ ---- ------- ------ ----------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------
  **Overall**           119                        107232   1.11   90   44517   2.02   1.82(1.66, 2.00)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.69(1.26, 2.28)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.69(1.18, 2.44)[\*\*](#t002fn003){ref-type="table-fn"}
  **Sex**                                                                                                                                                                                                      
  Women                 46                         33713    1.36   25   15002   1.67   1.22(1.02, 1.46)[\*\*\*](#t002fn004){ref-type="table-fn"}   0.98(0.58, 1.65)                                            0.98(0.52, 1.85)
  Men                   73                         73519    0.99   65   29515   2.20   2.22(1.98, 2.48)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.57(1.10, 2.23)[\*\*](#t002fn003){ref-type="table-fn"}     1.57(1.02, 2.41)[\*\*](#t002fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                                            0.06
  **Age, year**                                                                                                                                                                                                
  \<65                  21                         67869    0.31   17   30751   0.55   1.79(1.56, 2.05)[\*\*\*](#t002fn004){ref-type="table-fn"}   0.98(0.49, 1.98)                                            0.98(0.42, 2.30)
  65--75                51                         23387    2.18   42   8699    4.83   2.21(1.84, 2.66)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.76(1.12, 2.75)[\*\*](#t002fn003){ref-type="table-fn"}     1.76(1.02, 3.03)[\*\*](#t002fn003){ref-type="table-fn"}
  ≥75                   47                         15976    2.94   31   5066    6.12   2.08(1.72, 2.52)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.94(1.18, 3.19)[\*\*](#t002fn003){ref-type="table-fn"}     1.94(1.06, 3.56)[\*\*](#t002fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                                            0.92
  **Occupation**                                                                                                                                                                                               
  White collar          29                         48453    0.60   24   18665   1.29   2.15(1.84, 2.50)[\*\*\*](#t002fn004){ref-type="table-fn"}   2.19(1.21, 3.97)[\*\*](#t002fn003){ref-type="table-fn"}     2.19(1.06, 4.52)[\*\*](#t002fn003){ref-type="table-fn"}
  Blue collar           59                         38758    1.52   37   16878   2.19   1.44(1.23, 1.68)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.37(0.88, 2.13)                                            1.37(0.80, 2.35)
  Others                31                         20021    1.55   29   8974    3.23   2.09(1.72, 2.54)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.76(1.01, 3.06)[\*](#t002fn002){ref-type="table-fn"}       1.76(0.90, 3.45)
  P for interaction                                                                                                                                                                                            0.99
  **Comorbidity**                                                                                                                                                                                              
  No                    4                          24565    0.16   1    3705    0.27   1.66(1.19, 2.30)[\*\*\*](#t002fn004){ref-type="table-fn"}   2.97(0.31, 28.4)                                            2.97(0.19, 46.4)
  Yes                   115                        82667    1.39   89   40812   2.18   1.57(1.42, 1.74)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.90(1.43, 2.52)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.90(1.34, 2.68)[\*\*](#t002fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                                            0.60
  **Oral steroid**                                                                                                                                                                                             
  No                    64                         73083    0.88   34   23253   1.46   1.22(1.09, 1.37)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.82(1.16, 2.87)[\*\*](#t002fn003){ref-type="table-fn"}     1.82(1.05, 3.17)[\*\*](#t002fn003){ref-type="table-fn"}
  Yes                   55                         34149    1.61   56   21264   2.63   1.38(1.22, 1.55)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.63(1.10, 2.42)[\*\*](#t002fn003){ref-type="table-fn"}     1.63(1.01, 2.64)[\*\*](#t002fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                                            0.52
  **Follow-up, year**                                                                                                                                                                                          
  \<2                   35                         25420    1.38   31   11455   2.71   1.97(1.77, 2.18)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.78(1.05, 2.99)[\*](#t002fn002){ref-type="table-fn"}       1.78(0.94, 3.36)
  ≥2                    84                         81813    1.03   59   33062   1.78   1.74(1.57, 1.92)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.67(1.16, 2.40)[\*\*](#t002fn003){ref-type="table-fn"}     1.67(1.07, 2.59)[\*\*](#t002fn003){ref-type="table-fn"}

PY: person-year; Rate: incidence rate (per 1,000 person-years); IRR: incidence rate ratio; Adjusted HR^†^: multiple analysis including age, sex, occupation, drug of oral steroid, bisphosphonates, hormone replacement therapy (HRT), vitamin D supplements, and aromatase inhibitors and each comorbidity \[including hyperlipidemia, hypertension, diabetes, pneumonia, live cirrhosis, ischemia heart disease (IHD), stroke, chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD), alcohol-related illness, hyperparathyroidism, celiac disease, Chron's disease, and lower body weight\];

\*p\<0.05,

\*\*p\<0.02,

\*\*\*p\<0.001

The overall incidence of osteoporosis / fragility fracture was 9.61 per 1000 person--years and 7.29 per 1000 person--years in the RT and non-RT cohorts, respectively ([Table 3](#pone.0168673.t003){ref-type="table"}). [Fig 2B](#pone.0168673.g002){ref-type="fig"} shows that the cumulative incidence of osteoporosis / fragility fracture was higher in the RT cohort than in the non-RT cohort (log-rank test \< 0.001) at the end of the follow-up period. After adjustment for age, sex, drug use and comorbidities, the RT cohort was observed to be at a significantly higher risk of osteoporosis / fragility fracture compared with the non-RT cohort (adjusted HR = 1.42, 95% CI = 1.25--1.61; 98% CI = 1.21--1.65). The risk of osteoporosis was presented 1.36-fold (95% CI = 1.18--1.56; 98% CI = 1.14--1.61) in RT cohort. The RT cohort (except patients aged \<65 years) was significantly associated with a higher risk of osteoporosis / fragility fracture compared with the non-RT cohort, particularly at the age of 65--75 years and ≧75 years. The adjusted HR of osteoporosis / fragility fracture was higher in RT cohort regardless of white collar (adjusted HR = 1.57, 95% CI = 1.24--1.99; 98% CI = 1.18--2.10), and others (adjusted HR = 1.72, 95% CI = 1.34--2.22; 98% CI = 1.27--2.34).

10.1371/journal.pone.0168673.t003

###### Incidence and adjusted hazard ratio of osteoporosis / fragility fracture stratified by sex, age, comorbidity, oral steroid used and follow-up time between with and without respiratory tuberculosis cohorts.
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                                  Respiratory tuberculosis                                                                                                                                                                
  ------------------------------- -------------------------- -------- ------ ----- ------- ------ ----------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------
  **Overall**                     782                        107232   7.29   428   44517   9.61   1.32(1.21, 1.43)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.42(1.25, 1.61)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.42(1.21, 1.65)[\*\*](#t003fn003){ref-type="table-fn"}
  Osteoporosis (ICD-9-CM: 7330)   663                                 6.18   338           7.59   1.23(1.12, 1.34)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.36(1.18, 1.56)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.36(1.14, 1.61)[\*\*](#t003fn003){ref-type="table-fn"}
  **Sex**                                                                                                                                                                                                                 
  Women                           354                        33713    10.5   189   15002   12.6   1.20(1.04, 1.39)[\*](#t003fn002){ref-type="table-fn"}       1.11(0.92, 1.34)                                            1.11(0.89, 1.40)
  Men                             428                        73519    5.82   239   29515   8.10   1.39(1.26, 1.54)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.15(0.97, 1.36)                                            1.15(0.94, 1.41)
  P for interaction                                                                                                                                           0.34                                                        
  **Age, year**                                                                                                                                                                                                           
  \<65                            210                        67869    3.09   129   30751   4.19   1.36(1.21, 1.52)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.03(0.81, 1.30)                                            1.03(0.77, 1.37)
  65--75                          284                        23387    12.1   169   8699    19.4   1.60(1.37, 1.87)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.50(1.22, 1.85)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.50(1.17, 1.93)[\*\*](#t003fn003){ref-type="table-fn"}
  ≥75                             288                        15976    18.0   130   5066    25.7   1.42(1.21, 1.68)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.49(1.19, 1.86)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.49(1.14, 1.96)[\*\*](#t003fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                           0.74                                                        
  **Occupation**                                                                                                                                                                                                          
  White collar                    236                        48453    4.87   121   18665   6.48   1.33(1.16, 1.52)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.57(1.24, 1.99)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.57(1.18, 2.10)[\*\*](#t003fn003){ref-type="table-fn"}
  Blue collar                     359                        38758    9.26   184   16878   10.9   1.18(1.03, 1.34)[\*](#t003fn002){ref-type="table-fn"}       1.16(0.95, 1.40)                                            1.16(0.92, 1.46)
  Others                          187                        20021    9.34   123   8974    13.7   1.47(1.24, 1.74)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.72(1.34, 2.22)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.72(1.27, 2.34)[\*\*](#t003fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                           0.48                                                        
  **Comorbidity**                                                                                                                                                                                                         
  No                              62                         24565    2.52   5     3705    1.35   0.53(0.35, 0.82)[\*\*](#t003fn003){ref-type="table-fn"}     1.11(0.44, 2.81)                                            1.11(0.36, 3.43)
  Yes                             720                        82667    8.71   423   40812   10.4   1.19(1.09, 1.30)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.48(1.31, 1.68)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.48(1.28, 1.72)[\*\*](#t003fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                           0.38                                                        
  **Oral steroid**                                                                                                                                                                                                        
  No                              516                        73083    7.06   200   23253   8.60   1.22(1.09, 1.37)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.40(1.17, 1.67)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.40(1.13, 1.73)[\*\*](#t003fn003){ref-type="table-fn"}
  Yes                             266                        34149    7.79   228   21264   10.7   1.38(1.22, 1.55)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.46(1.21, 1.76)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.46(1.16, 1.83)[\*\*](#t003fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                           0.73                                                        
  **Follow-up, year**                                                                                                                                                                                                     
  \<2                             257                        25419    10.1   162   11455   14.1   1.40(1.28, 1.53)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.59(1.28, 1.97)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.28(1.08, 1.52)[\*\*](#t003fn003){ref-type="table-fn"}
  ≥2                              525                        81813    6.42   266   33062   8.05   1.25(1.15, 1.37)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.33(1.14, 1.57)[\*\*\*](#t003fn004){ref-type="table-fn"}   1.67(1.07, 2.59)[\*\*](#t003fn003){ref-type="table-fn"}

PY: person-year; Rate: incidence rate (per 1,000 person-years); IRR: incidence rate ratio; Adjusted HR^†^: multiple analysis including age, sex, occupation, drug of oral steroid, bisphosphonates, hormone replacement therapy (HRT), vitamin D supplements, and aromatase inhibitors and each comorbidity \[including hyperlipidemia, hypertension, diabetes, pneumonia, live cirrhosis, ischemia heart disease (IHD), stroke, chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD), alcohol-related illness, hyperparathyroidism, celiac disease, Chron's disease, and lower body weight\];

\*p\<0.05,

\*\*p\<0.02,

\*\*\*p\<0.001

The statistically significant increased risk of osteoporosis / fragility fracture was observed in patients with comorbidities (adjusted HR = 1.48, 95% CI = 1.31--1.68; 98% CI = 1.28--1.72) in the RT cohort. The RT cohort without oral steroid use was at a 1.40-fold increased risk of osteoporosis / fragility fracture compared with the non-RT cohort without oral steroid use (adjusted HR = 1.40, 95% CI = 1.17--1.67; 98% CI = 1.13--1.73), and the RT cohort was at a 1.46-fold increased osteoporosis / fragility fracture risk compared with the non-RT cohort with oral steroid use (adjusted HR = 1.46, 95% CI = 1.21--1.76; 98% CI = 1.16--1.83). The adjusted HR of osteoporosis / fragility fracture was significantly higher in the first two follow-up year (adjusted HR = 1.59, 95% CI = 1.28--1.97; 98% CI = 1.08--1.52) and in later on (adjusted HR = 1.33, 95% CI = 1.14--1.57; 98% CI = 1.07--2.59).

The incidence rate of fragility fracture was higher for those with comorbidities of hypertension, diabetes, pneumonia, live cirrhosis, and IHD in both cohorts ([Table 4](#pone.0168673.t004){ref-type="table"}). The risk of fragility fracture was higher among patients without hypertension (adjusted HR = 2.81, 95% CI = 1.44--5.51) than patients with hypertension (adjusted HR = 1.52, 95% CI = 0.97--2.36) (P for interaction = 0.02).

10.1371/journal.pone.0168673.t004

###### Incidence and adjusted hazard ratio of fragility fracture stratified by different comorbidity in respiratory tuberculosis and non-respiratory tuberculosis groups.
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                                Respiratory tuberculosis   Compared to without respiratory tuberculosis                                                                                                                                                      
  ----------------------------- -------------------------- ---------------------------------------------- ------ ---- ------- ------ ----------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------
  **Hyperlipidemia**                                                                                                                                                                                                                                         
  No                            90                         78246                                          1.15   66   32997   2.00   1.77(1.59, 1.96)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.73(1.22, 2.46)[\*\*](#t004fn002){ref-type="table-fn"}     1.73(1.13, 2.66)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           29                         28986                                          1.00   24   11520   2.08   2.11(1.77, 2.52)[\*\*\*](#t004fn003){ref-type="table-fn"}   2.17(1.22, 3.86)[\*\*](#t004fn002){ref-type="table-fn"}     2.17(1.08, 4.37)[\*\*](#t004fn002){ref-type="table-fn"}
  P for interaction                                                                                                                                                                              0.52                                                        
  **Hypertension**                                                                                                                                                                                                                                           
  No                            31                         57441                                          0.54   37   24315   1.52   2.86(2.50, 3.27)[\*\*\*](#t004fn003){ref-type="table-fn"}   2.81(1.62, 4.89)[\*\*\*](#t004fn003){ref-type="table-fn"}   2.81(1.44, 5.51)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           88                         49792                                          1.77   53   20202   2.62   1.51(1.33, 1.71)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.52(1.05, 2.18)\*                                          1.52(0.97, 2.36)
  P for interaction                                                                                                                                                                              0.02                                                        
  **Diabetes**                                                                                                                                                                                                                                               
  No                            85                         84771                                          1.00   66   33583   1.97   1.99(1.79, 2.20)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.86(1.30, 2.66)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.86(1.21, 2.87)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           34                         22462                                          1.51   24   10934   2.19   1.49(1.25, 1.78)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.69(0.97, 2.95)                                            1.69(0.85, 3.33)
  P for interaction                                                                                                                                                                              0.31                                                        
  **Pneumonia**                                                                                                                                                                                                                                              
  No                            52                         70796                                          0.73   26   19286   1.35   1.87(1.64, 2.14)[\*\*\*](#t004fn003){ref-type="table-fn"}   2.25(1.36, 3.72)[\*\*](#t004fn002){ref-type="table-fn"}     2.25(1.22, 4.15)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           67                         36436                                          1.84   64   25231   2.54   1.40(1.23, 1.59)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.62(1.13, 2.34)[\*\*](#t004fn002){ref-type="table-fn"}     1.62(1.04, 2.53)[\*\*](#t004fn002){ref-type="table-fn"}
  P for interaction                                                                                                                                                                              0.22                                                        
  **Live cirrhosis**                                                                                                                                                                                                                                         
  No                            81                         78405                                          1.03   59   27834   2.12   2.08(1.86, 2.32)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.89(1.31, 2.74)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.89(1.21, 2.96)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           38                         28828                                          1.32   31   16683   1.86   1.44(1.23, 1.70)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.66(0.99, 2.78)                                            1.66(0.88, 3.11)
  P for interaction                                                                                                                                                                              0.38                                                        
  **IHD**                                                                                                                                                                                                                                                    
  No                            70                         80293                                          0.87   51   32385   1.57   1.84(1.65, 2.05)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.98(1.32, 2.96)[\*\*](#t004fn002){ref-type="table-fn"}     1.98(1.21, 3.24)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           49                         26939                                          1.82   39   12132   3.21   1.79(1.53, 2.11)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.66(1.06, 2.59)\*                                          1.66(0.96, 2.86)
  P for interaction                                                                                                                                                                              0.71                                                        
  **ESRD**                                                                                                                                                                                                                                                   
  No                            119                        105958                                         1.12   89   43658   2.04   1.85(1.69, 2.02)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.80(1.33, 2.43)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.80(1.25, 2.59)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           0                          1274                                           0      1    859     1.16   \-                                                          \-                                                          \-
  P for interaction                                                                                                                                                                              0.97                                                        
  **Alcohol-related illness**                                                                                                                                                                                                                                
  No                            118                        104094                                         1.13   83   41430   2      1.79(1.63, 1.96)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.72(1.27, 2.34)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.72(1.19, 2.50)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           1                          3138                                           0.32   7    3086    2.27   7.67(4.11, 14.3)[\*\*\*](#t004fn003){ref-type="table-fn"}   8.67(0.84, 80.1)                                            8.67(0.50, 149.9)
  P for interaction                                                                                                                                                                              0.11                                                        
  **Hyperparathyroidism**                                                                                                                                                                                                                                    
  No                            118                        107120                                         1.1    90   44375   2.03   1.87(1.71, 2.05)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.83(1.36, 2.47)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.83(1.27, 2.64)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           1                          112                                            8.95   0    142     0      \-                                                          \-                                                          \-
  P for interaction                                                                                                                                                                              0.96                                                        
  **Celiac disease**                                                                                                                                                                                                                                         
  No                            119                        107232                                         1.11   90   44505   2.02   1.85(1.69, 2.03)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.81(1.35, 2.45)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.81(1.26, 2.61)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           0                          0                                              \-     0    12      0      \-                                                          \-                                                          \-
  P for interaction                                                                                                                                                                              \-                                                          
  **Chron's disease**                                                                                                                                                                                                                                        
  No                            115                        105230                                         1.09   88   43519   2.02   1.88(1.72, 2.06)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.88(1.39, 2.54)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.88(1.30, 2.71)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           4                          2002                                           2.00   2    997     2.01   1.00(0.53, 1.87)                                            0.12(0.01, 3.18)                                            0.12(0.002, 6.50)
  P for interaction                                                                                                                                                                              0.38                                                        
  **Lower body weight**                                                                                                                                                                                                                                      
  No                            115                        104556                                         1.10   85   42491   2.00   1.85(1.69, 2.03)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.83(1.35, 2.48)[\*\*\*](#t004fn003){ref-type="table-fn"}   1.83(1.26, 2.65)[\*\*](#t004fn002){ref-type="table-fn"}
  Yes                           4                          2676                                           1.49   5    2026    2.47   1.62(0.99, 2.66)                                            1.70(0.33, 8.70)                                            1.70(0.23, 12.4)
  P for interaction                                                                                                                                                                              0.97                                                        

PY: person-year; Rate: incidence rate (per 1,000 person-years); IRR: incidence rate ratio; Adjusted HR^†^: multiple analysis including age, sex, occupation, drug of oral steroid, bisphosphonates, hormone replacement therapy (HRT), vitamin D supplements, and aromatase inhibitors and each comorbidity \[including hyperlipidemia, hypertension, diabetes, pneumonia, live cirrhosis, ischemia heart disease (IHD), stroke, chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD), alcohol-related illness, hyperparathyroidism, celiac disease, Chron's disease, and lower body weight\];

\*\*p\<0.02,

\*\*\*p\<0.001

[Table 5](#pone.0168673.t005){ref-type="table"} shows the osteoporosis / fragility fracture risk between the RT and non-RT cohorts stratified by different comorbidities. Our results consistently showed that the RT cohort was significantly associated with an increased risk of osteoporosis / fragility fracture compared with the non-RT cohort in the presence of different comorbidities, such as hyperlipidemia, hypertension, diabetes, pneumonia, live cirrhosis, and IHD. The RT cohort without lower body weight have the higher risk of osteoporosis / fragility fracture (adjusted HR = 1.41, 95% CI = 1.24--1.60; 98% CI = 1.20--1.65), compared with the non-RT cohort also.

10.1371/journal.pone.0168673.t005

###### Incidence and adjusted hazard ratio of osteoporosis / fragility fracture stratified by different comorbidity in respiratory tuberculosis and non-respiratory tuberculosis groups.
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                                Respiratory tuberculosis   Compared to without respiratory tuberculosis                                                                                                                                                       
  ----------------------------- -------------------------- ---------------------------------------------- ------ ----- ------- ------ ----------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------
  **Hyperlipidemia**                                                                                                                                                                                                                                          
  No                            533                        78246                                          6.81   295   32997   8.94   1.31(1.19, 1.45)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.21, 1.66)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.17, 1.72)\*\*
  Yes                           249                        28986                                          8.59   133   11520   11.5   1.34(1.15, 1.57)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.43(1.14, 1.79)[\*\*](#t005fn003){ref-type="table-fn"}     1.43(1.09, 1.88)\*\*
  P for interaction                                                                                                                                                                               0.72                                                        
  **Hypertension**                                                                                                                                                                                                                                            
  No                            259                        57441                                          4.51   168   24315   6.91   1.53(1.36, 1.73)                                            1.50(1.21, 1.87)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.50(1.15, 1.96)\*\*\*\*
  Yes                           523                        49792                                          10.5   260   20202   12.9   1.23(1.10, 1.37)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.34(1.15, 1.58)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.34(1.11, 1.63)[\*\*](#t005fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                               0.048                                                       
  **Diabetes**                                                                                                                                                                                                                                                
  No                            584                        84771                                          6.89   297   33583   8.84   1.28(1.17, 1.41)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.39(1.20, 1.63)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.39(1.16, 1.68)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           198                        22462                                          8.82   131   10934   12     1.36(1.16, 1.59)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.12, 1.80)[\*\*](#t005fn003){ref-type="table-fn"}     1.42(1.07, 1.89)[\*\*](#t005fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                               0.71                                                        
  **Pneumonia**                                                                                                                                                                                                                                               
  No                            452                        70796                                          6.38   159   19286   8.24   1.29(1.14, 1.46)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.52(1.26, 1.84)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.52(1.20, 1.92)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           330                        36436                                          9.06   269   25231   10.7   1.18(1.05, 1.32)[\*\*](#t005fn003){ref-type="table-fn"}     1.33(1.12, 1.58)[\*\*](#t005fn003){ref-type="table-fn"}     1.33(1.08, 1.64)[\*\*](#t005fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                               0.19                                                        
  **Live cirrhosis**                                                                                                                                                                                                                                          
  No                            541                        78405                                          6.9    261   27834   9.38   1.36(1.23, 1.50)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.43(1.22, 1.68)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.43(1.18, 1.74)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           241                        28828                                          8.36   167   16683   10     1.20(1.04, 1.38)[\*](#t005fn002){ref-type="table-fn"}       1.37(1.11, 1.69)[\*\*](#t005fn003){ref-type="table-fn"}     1.37(1.06, 1.77)[\*\*](#t005fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                               0.87                                                        
  **IHD**                                                                                                                                                                                                                                                     
  No                            465                        80293                                          5.79   251   32385   7.75   1.34(1.21, 1.48)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.51(1.27, 1.79)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.51(1.23, 1.86)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           317                        26939                                          11.8   177   12132   14.6   1.24(1.08, 1.43)[\*\*](#t005fn003){ref-type="table-fn"}     1.30(1.07, 1.58)[\*\*](#t005fn003){ref-type="table-fn"}     1.30(1.02, 1.64)[\*\*](#t005fn003){ref-type="table-fn"}
  P for interaction                                                                                                                                                                               0.26                                                        
  **ESRD**                                                                                                                                                                                                                                                    
  No                            777                        105958                                         7.33   419   43658   9.6    1.31(1.20, 1.42)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.40(1.23, 1.60)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.40(1.20, 1.64)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           5                          1274                                           3.92   9     859     10.5   2.67(1.46, 4.88)[\*\*](#t005fn003){ref-type="table-fn"}     2.24(0.56, 8.98)                                            2.24(0.41, 12.2)
  P for interaction                                                                                                                                                                               0.13                                                        
  **Alcohol-related illness**                                                                                                                                                                                                                                 
  No                            769                        104094                                         7.39   410   41430   9.9    1.34(1.23, 1.46)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.40(1.23, 1.59)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.40(1.19, 1.64)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           13                         3138                                           4.14   18    3086    5.83   1.41(0.96, 2.07)                                            2.61(1.14, 5.95)[\*](#t005fn002){ref-type="table-fn"}       2.61(0.96, 7.12)
  P for interaction                                                                                                                                                                               0.35                                                        
  **Hyperparathyroidism**                                                                                                                                                                                                                                     
  No                            780                        107120                                         7.28   427   44375   9.62   1.32(1.22, 1.43)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.25, 1.61)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.21, 1.66)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           2                          112                                            17.9   1     142     7.06   0.39(0.07, 2.35)                                            \-                                                          \-
  P for interaction                                                                                                                                                                               0.29                                                        
  **Celiac disease**                                                                                                                                                                                                                                          
  No                            782                        107232                                         7.29   428   44505   9.62   1.32(1.22, 1.43)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.25, 1.61)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.21, 1.65)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           0                          0                                              \-     0     11.7    0      \-                                                          \-                                                          
  P for interaction                                                                                                                                                                               \-                                                          
  **Chron's disease**                                                                                                                                                                                                                                         
  No                            766                        105230                                         7.28   420   43519   9.65   1.33(1.22, 1.44)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.25, 1.62)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.42(1.22, 1.67)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           16                         2002                                           7.99   8     997     8.02   1.00(0.56, 1.80)                                            0.85(0.31, 2.33)                                            0.85(0.25, 2.90)
  P for interaction                                                                                                                                                                               0.41                                                        
  **Lower body weight**                                                                                                                                                                                                                                       
  No                            768                        104556                                         7.35   413   42491   9.72   1.32(1.22, 1.44)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.41(1.24, 1.60)[\*\*\*](#t005fn004){ref-type="table-fn"}   1.41(1.20, 1.65)[\*\*](#t005fn003){ref-type="table-fn"}
  Yes                           14                         2676                                           5.23   15    2026    7.4    1.42(0.91, 2.19)                                            2.03(0.86, 4.82)                                            2.03(0.71, 5.82)
  P for interaction                                                                                                                                                                               0.74                                                        

PY: person-year; Rate: incidence rate (per 1,000 person-years); IRR: incidence rate ratio; Adjusted HR^†^: multiple analysis including age, sex, occupation, drug of oral steroid, bisphosphonates, hormone replacement therapy (HRT), vitamin D supplements, and aromatase inhibitors and each comorbidity \[including hyperlipidemia, hypertension, diabetes, pneumonia, live cirrhosis, ischemia heart disease (IHD), stroke, chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD), alcohol-related illness, hyperparathyroidism, celiac disease, Chron's disease, and lower body weight\];

\*p\<0.05,

\*\*p\<0.02,

\*\*\*p\<0.001

The RT cohort without oral steroid use was at a 1.87-fold increased risk of fragility fractures (adjusted HR = 1.87, 95% CI = 1.20--2.90; 98% CI = 1.09--3.19) compared with the non-RT cohort ([Table 6](#pone.0168673.t006){ref-type="table"}). The RT cohort using oral steroid demonstrated a statistically significant increased risk of fragility fractures in men (adjusted HR = 1.89, 95% CI = 1.19--3.00; 98% CI = 1.07--3.32). Similar results were observed for osteoporosis / fragility fracture.

10.1371/journal.pone.0168673.t006

###### Adjusted hazard ratio of fragility fractures and osteoporosis / fragility fracture found the associated with respiratory tuberculosis and drugs.
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                                      Event   PY       Rate   Adjusted HR^†^ (95% CI)                                     Adjusted HR^†^ (98% CI)
  ----------------------------------- ------- -------- ------ ----------------------------------------------------------- ---------------------------------------------------------
  **Fragility fractures**                                                                                                 
  **Overall**                                                                                                             
  Without respiratory tuberculosis    119     107232   1.11   1.00                                                        1.00
  With respiratory tuberculosis                                                                                           
  Without oral steroid                34      23253    1.46   1.87(1.20, 2.90)[\*\*](#t006fn003){ref-type="table-fn"}     1.87(1.09, 3.19)[\*\*](#t006fn003){ref-type="table-fn"}
  With oral steroid                   56      21264    2.63   1.58(1.08, 2.31)[\*](#t006fn002){ref-type="table-fn"}       1.58(0.99, 2.51)
  **Men**                                                                                                                 
  Without respiratory tuberculosis    73      73519    0.99   1.00                                                        1.00
  With respiratory tuberculosis                                                                                           
  Without oral steroid                25      14837    1.68   2.26(1.32, 3.85)[\*\*](#t006fn003){ref-type="table-fn"}     2.26(1.18, 4.33)[\*\*](#t006fn003){ref-type="table-fn"}
  With oral steroid                   40      14678    2.73   1.89(1.19, 3.00)[\*\*](#t006fn003){ref-type="table-fn"}     1.89(1.07, 3.32)[\*\*](#t006fn003){ref-type="table-fn"}
  **Women**                                                                                                               
  Without respiratory tuberculosis    46      33713    1.36   1.00                                                        1.00
  With respiratory tuberculosis                                                                                           
  Without oral steroid                9       8416     1.07   1.25(0.56, 2.77)                                            1.25(0.47, 3.29)
  With oral steroid                   16      6586     2.43   1.09(0.55, 2.15)                                            1.09(0.47, 2.49)
  Osteoporosis /fragility fractures                                                                                       
  **Overall**                                                                                                             
  Without respiratory tuberculosis    782     107232   7.29   1.00                                                        1.00
  With respiratory tuberculosis                                                                                           
  Without oral steroid                200     23253    8.60   1.41(1.19, 1.67)[\*\*\*](#t006fn004){ref-type="table-fn"}   1.41(1.14, 1.74)[\*\*](#t006fn003){ref-type="table-fn"}
  With oral steroid                   228     21264    10.7   1.42(1.19, 1.70)[\*\*\*](#t006fn004){ref-type="table-fn"}   1.42(1.14, 1.77)[\*\*](#t006fn003){ref-type="table-fn"}
  **Men**                                                                                                                 
  Without respiratory tuberculosis    428     73519    5.82   1.00                                                        1.00
  With respiratory tuberculosis                                                                                           
  Without oral steroid                107     14837    7.21   1.56(1.23, 1.98)[\*\*\*](#t006fn004){ref-type="table-fn"}   1.56(1.17, 2.09)[\*\*](#t006fn003){ref-type="table-fn"}
  With oral steroid                   132     14678    8.99   1.43(1.13, 1.81)[\*\*](#t006fn003){ref-type="table-fn"}     1.43(1.08, 1.90)[\*\*](#t006fn003){ref-type="table-fn"}
  **Women**                                                                                                               
  Without respiratory tuberculosis    354     33712    10.5   1.00                                                        1.00
  With respiratory tuberculosis                                                                                           
  Without oral steroid                93      8416     11.1   1.25(0.98, 1.61)                                            1.25(0.92, 1.70)
  With oral steroid                   96      6586     14.6   1.42(1.07, 1.89)[\*](#t006fn002){ref-type="table-fn"}       1.42(1.00, 2.01)

PY, person-year; Rate, incidence rate (per 1,000 person-years); Adjusted HR^†^: multiple analysis including occupation, drug of oral steroid, bisphosphonates, hormone replacement therapy (HRT), vitamin D supplements, and aromatase inhibitors and each comorbidity \[such as hyperlipidemia, hypertension, diabetes, pneumonia, live cirrhosis, ischemia heart disease (IHD), stroke, chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD), alcohol-related illness, hyperparathyroidism, celiac disease, crohn disease, and lower body weight\];

\*p\<0.05,

\*\*p\<0.02,

\*\*\*p\<0.001

Discussion {#sec012}
==========

A published meta-analysis including 167 studies evaluated the risk factors for a low bone marrow density (BMD)-related fracture in men and women, and reported age (\>70 years), low body weight \[body mass index (BMI) \<20 to 25 kg/m^2^\], weight loss (\>10%), physical inactivity, prolonged corticosteroid use, and previous osteoporotic fracture as high risk factors \[[@pone.0168673.ref020]\]. An additional 102 studies assessed 15 other proposed risk factors but provided insufficient evidence in support of a male population \[[@pone.0168673.ref020]\]. This study suggested that the incidence of fragility fracture (adjusted HR = 1.69), osteoporosis / fragility fracture (adjusted HR = 1.42) in the RT cohort is higher than in the non-RT cohort, irrespective of age, sex, steroids use and comorbidities.

Respiratory tuberculosis is one of the diseases characterized granuloma formation which was controlled by cellular immune reactions, interferon-gamma (INF-gamma) which mediate inflammatory reactions increased in the tuberculosis \[[@pone.0168673.ref021]\]. Expression levels of IFN-gamma have a positive correlation to bone fracture \[[@pone.0168673.ref022]\]. The cytokine IFN-gamma stimulates neopterin release. High levels of neopterin were associated with increased hip fracture risk \[[@pone.0168673.ref023]\]. These previous finding imply that the RT associated with the bone fracture, even without comorbidities or steroid use. Holloway et al. study in 3 to 5% of active cases of tuberculosis \[[@pone.0168673.ref024]\] with bone fracture (e.g. compression fracture) in accordance with our study \[[@pone.0168673.ref025]\]. However, these hypothesis warrant further research.

Vitamin D deficiency and a low calcium intake were risk factors for osteoporosis observed in men. A study conducted by Ho-Pham et al suggested that vitamin D deficiency was also reported to be a risk factor for tuberculosis in men but not in women \[[@pone.0168673.ref026]\]. The dual effect of vitamin D deficiency on RT and osteoporosis may confound the association between RT and bone fracture. These factors support the higher risk of the fragility fracture (adjusted HR = 1.57, *P for interaction = 0*.*06*) observed in a male population than in female belonging to the RT cohort. Dehydroepiandrosterone (DHEA) and testosterone levels were profoundly reduced in the RT cohort along with a modest increase in cortisol and estradiol levels \[[@pone.0168673.ref027]\]. The low DHEA increased the RANAL activity owing to the decrease of the ratio of OPG / RANKL mRNA in osteoblasts \[[@pone.0168673.ref028]\], the high cortisol inhibit the OPG activity, thus resulting in the osteoporosis \[[@pone.0168673.ref008]\]. Wang NB et al, they found the osteoporosis with low BMD in the PTB patients also \[[@pone.0168673.ref029]\]. BMD changes were more marked in patients with RT than in those of the same age group with other chronic lung diseases agree this finding also \[[@pone.0168673.ref030]\]. The osteoporosis contribute to the bone fracture. Therefore, the adjusted HR of the RT cohort for fragility fracture was higher than that of the non-RT cohort, particularly in men (for men, adjusted HR = 1.57, *p \<0*.*001*; for women, adjusted HR = 0.98; *p\>0*.*05*).

Vitamin D deficiency was common in both underweight and normal-weight patients, but an association between vitamin D deficiency and reduced femur neck T scores was indicated only in the underweight patients with RT \[[@pone.0168673.ref031]\]. The median 25(OH)D level increased after tuberculosis treatment. In Taiwan, patients with RT receive antituberculosis (anti-TB) treatment \[[@pone.0168673.ref016]\] or anti-TB with a short-term low dose steroid may increase the BMI of patients with RT and malnutrition \[[@pone.0168673.ref032]\]. The BMD of Taiwanese women shows a positive relationship to body weight and BMI in the femoral neck fracture group \[[@pone.0168673.ref033]\]. Similarly, patients with inhaled steroid use \[[@pone.0168673.ref034]\] may have the less incidence of the osteoporosis \[[@pone.0168673.ref035]\]. Therefore, RT cohort with steroid use and anti-TB drug may have an increased BMI \[[@pone.0168673.ref035]\], 25(OH)D level \[[@pone.0168673.ref031]\], and BMD \[[@pone.0168673.ref035]\]; these may explain the RT cohort with the lower body weight reveal no significant risk of the incident fragility fracture (aHR = 1.70, *p value \>0*.*05*) or osteoporosis / fragility fracture (aHR = 2.03, *p value \>0*.*05*). These hypotheses warrant research.

The Nanjundaiah et al. report, Lewis rats by injection of heat-killed *M*. *tuberculosis* H37Ra (Mtb). The antigen-presenting cells (APCs) took up the microbial antigens. APCs process antigens and then present these Mtb to antigen-specific T cells. These antigen-primed T cells then migrate into the joints, and release proinflammatory cytokines (osteopontin, tumor necrosis factor-α, interleukin) locally leading to arthritic inflammation. These cytokines also stimulate the production of RANKL/MCSF, which activates osteoclasts producing cathepsin K (Cat K) and matrix metalloproteases (MMPs) resulting in bone damage such as osteoporosis \[[@pone.0168673.ref036]\]. Similarly, sinomenine could attenuate osteoclast formation and Mtb-induced bone loss by mediating RANKL signaling pathways in Li et al study support the RT presenting as systemic inflammation and contribute to the osteoporosis in our study \[[@pone.0168673.ref037]\].

Women who lived in institutions and had osteoporosis, RT, and cardiac diseases (hypertension) were at risk of a contralateral hip fracture after the initial hip fracture \[[@pone.0168673.ref038]\]. Activity restriction led to an increased bone resorption in hospitalized women, which possibly affected the risk of osteopenia and osteoporosis \[[@pone.0168673.ref039]\]. In our study, the patients with the hypertension (aHR = 1.34, *p value \<0*.*05*) and IHD (aHR = 1.30, *p value \<0*.*05*) were association with the osteoporosis / fragility fracture in RT cohort. Meanwhile, women in the RT cohort with the oral steroid use are at an increased risk of osteoporosis / fragility fracture (aHR = 1.42, 95% CI; *p value \<0*.*05*) than the non-RT cohort. These finding in line with previous study. Yet, this result need the random control trial for confirmation.

Previous studies have reported that metabolic-syndrome-related diseases such as hyperlipidemia, hypertension, diabetes, ischemic heart diseases, ESRD \[[@pone.0168673.ref010]\], and liver cirrhosis \[[@pone.0168673.ref011]\] were more common in patients with osteoporotic fracture. This study also demonstrated that metabolic diseases increased the risk of bone fracture, osteoporosis / fragility fracture. Meanwhile, alcohol-related illness were associated with the bone fractures, osteoporosis / fragility fracture in RT cohort also. Previous studies have rarely reported pneumonia as a risk factor of osteoporosis. In this study, we observed that both acute pneumonia (viral and bacterial) and chronic respiratory infectious diseases (RT) increased the risk of fragility fracture (aHR = 1.69), osteoporosis / fragility fracture (aHR = 1.42).

Respiratory infections were frequently observed in elderly patients with malnutrition. The combined effect of malnutrition, respiratory infection, and physical inactivity contributes to osteoporosis / incident fragility fracture \[[@pone.0168673.ref040]\]. In our study, we found that a higher incidence of bone fracture, osteoporosis / fragility fracture among the frequently hospitalized patients with RT even without low body weight, or without steroid use; compared with patients without RT. This study increases physicians awareness of incident bone fracture associated with RT.

Limitations {#sec013}
===========

Several limitations must be considered when interpreting these findings. The NHIRD does not provide detailed lifestyle information such as smoking, BMI, and physical activity, which were potential confounding factors in this study. However, anti-TB treatment and lifestyle modification of patients with RT may implicate these factors in accelerated bone fracture or osteoporosis / fragility fracture observed in RT. Additionally, information on osteoporosis severity scales such as disease activity, functional impairment, and physical damage may lead to underdiagnosis of this metabolic syndrome. Insufficient drug data such as oral antidiabetic drugs to adjust for the outcomes of interest could be another limitation. The evidence derived from this retrospective cohort study is generally of lower methodological evidence than that from randomized controlled trials because a retrospective cohort study is subject to many biases due to lack of the necessary adjustments for possible confounding factors (such as lack of the important data like serum levels OPG, RANKL, osteoclast activity markers and bone formation markers; and individual data of the histological or densitometric changes in bone). The Nanjundaiah and Li et al. study were experimental study in animals. Therefore, further investigation with a prospective and randomized controlled study design to reveal the cause-effect between RT and bone fracture or osteoporosis / fragility fracture would be worthwhile. In addition, lack of BMD data to do the optimal diagnosis of osteoporosis in the NHIRD is the study limitation. However, NHIRD covers a highly representative sample of Taiwan's general population because the reimbursement policy is universal and operated by a single-buyer, the government in Taiwan. All insurance claims should be scrutinized by medical reimbursement specialists and peer review according to the standard diagnosed criteria in the study. If these doctors or hospitals make wrong diagnoses or coding, they will be punished with a lot of penalties. Therefore, the diagnoses of osteoporosis based on ICD-9 codes in this study were highly reliable. In addition, fracture reported here is based on ICD codes, not X-ray report. We can't distinguish between atraumatic and traumatic fractures. Meanwhile, Underlying causes of pathological fractures include osteoporosis, metastatic bone tumor, osteomyelitis, Paget's disease, disuse atrophy, hyperparathyroidism, and nutritional or congenital disorders \[Coding for Fractures: For The Record Vol. 20 No. 24 P. 28 (Great Valley Publishing Co., Inc)\]. After we did analyses, we didn't find the coding of the \[ICD-9-CM -198.5, Secondary malignant neoplasm of bone and bone marrow; ICD-9-CM---170.9, Malignant neoplasm of bone and articular cartilage, site unspecified; ICD-9-CM-731.0, Osteitis deformans without mention of bone tumor\] in the RT cohort. The impact of these confounding factors on the fragility fractures needs further investigation. Finally, when performing several tests, increasing the family-wise error rate (FWER, the probability of rejecting at least one null hypothesis erroneously). In statistics, FWER is the probability of making one or more false discoveries, or typeΙerrors when performing multiple hypotheses tests. The Bonferroni adjustment will always provide strong control of the family-wise error rate \[[@pone.0168673.ref041]\]. If the number of comparisons in the test becomes large, the test may become too conservative and no longer allows us to find anything significant \[[@pone.0168673.ref042]\].

Strength {#sec014}
========

The nationwide population-based longitudinal cohort study used to investigate the risk factors of incident bone fracture, osteoporosis / fragility fracture in an Asian population with RT was the strength of this study. We investigated drug effects such as oral steroid of the impact on the osteoporosis. We have replaced the smoking history data with the comorbidity which were associated with smoking such as IHD, stroke and COPD for adjustment. Meanwhile the life style such as drinking (alcohol-related disease) and patients received anti-osteoporosis drugs were included for analysis also. Furthermore, the study included participants from the general population representative of a true population, thereby improving the generalizability of our results. Even the BMD unavailable in this study; the policy of diagnosis of the osteoporosis is well established in Taiwan \[[@pone.0168673.ref043]\]. The coding the osteoporosis under the "guideline for the prevention and treatment of osteoporosis in Taiwan" at most healthcare system \[[@pone.0168673.ref044]\]. This multidisciplinary system may avoid the diagnosis bias.

Conclusion {#sec015}
==========

The Respiratory tuberculosis associated with the incident fragility fracture, either in men or absence of oral steroid use

Supporting Information {#sec016}
======================

###### 

(DOC)

###### 

Click here for additional data file.

aHR

:   adjusted hazard ratio

APCs

:   antigen-presenting cells

Cat K

:   cathepsin K

CI

:   confidence interval

HCV

:   hepatitis C virus

HRT

:   hormone replacement therapy

INF-gamma

:   interferon-gamma

LHID 2000

:   Longitudinal Health Insurance Database 2000

MMPs

:   matrix metalloproteases

Mtb

:   *M*. *tuberculosis*

NHIRD

:   National Health Insurance Research Database

NHI

:   National Health Insurance

NHRI

:   National Health Research Institutes

OPG

:   osteoprotegerin

PTB

:   pulmonary tuberculosis

PTH

:   Parathyroid hormone

RANKL

:   receptor activator of nuclear factor kappa-B ligand

RT

:   respiratory tuberculosis
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